August 11, 2011 -- WuXi PharmaTech, the NY-listed CRO, reported Q2 revenues climbed 25% to $101.1 million, breaking the $100 million mark for the first time. Although its mainstay Laboratory Services business was up a solid 10%, the big winner was, once again, Manufacturing Services. That segment leaped almost 150% ahead to $21 million in the quarter. All the numbers were slightly ahead of WuXi’s always conservative guidance. More details....
Stock Symbol: (NYSE: WX)
